Neonatal-onset multisystem inflammatory disease
Neonatal-onset multisystem inflammatory disease (NOMID), also known as Chronic Infantile Neurological Cutaneous and Articular syndrome (CINCA), is a rare genetic disorder that affects multiple systems of the body. This condition is characterized by a triad of symptoms: skin rash, joint involvement, and chronic meningitis.
Symptoms and Signs[edit | edit source]
The symptoms of NOMID usually appear shortly after birth. The most common symptom is a skin rash that typically appears within the first six weeks of life. Other symptoms may include fever, joint pain, and inflammation of the membranes surrounding the brain and spinal cord (meningitis). In some cases, individuals with NOMID may also experience hearing loss, vision problems, and developmental delays.
Causes[edit | edit source]
NOMID is caused by mutations in the NLRP3 gene. This gene provides instructions for making a protein that is involved in the body's immune response. Mutations in the NLRP3 gene lead to continuous activation of the immune system, resulting in widespread inflammation and the symptoms of NOMID.
Diagnosis[edit | edit source]
Diagnosis of NOMID is based on the presence of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and specialized tests. Genetic testing can confirm a diagnosis.
Treatment[edit | edit source]
Treatment of NOMID is aimed at managing symptoms and preventing complications. This may include medications to reduce inflammation and pain, physical therapy to improve joint mobility, and regular monitoring for potential complications.
Prognosis[edit | edit source]
The prognosis for individuals with NOMID varies. With early diagnosis and appropriate treatment, many individuals with NOMID can lead productive lives. However, without treatment, NOMID can lead to severe complications, including disability and premature death.
See Also[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD